Program Objectives:

Describe the incidence and burden of early-onset severe toxicity in patients receiving 5-FU and capecitabine
Describe mechanism of action of 5-FU and its cytotoxic metabolites as it relates to the causes of early-onset severe toxicity
Recognize signs and symptoms of 5-FU and capecitabine early-onset severe toxicity
Summarize evidence supporting emergency treatment for patients with early-onset severe toxicity and following 5-FU and capecitabine overdoses
Review the importance of prompt treatment of overdoses and early-onset severe toxicity
Educate patients, caregivers, and colleagues about the importance of recognizing and urgently treating early-onset severe toxicity of 5-FU and capecitabine

Alice Beers BSN, OCN, NPD-BC

Oncology Nurse Navigator, MedStar Georgetown Cancer Network at Washington Cancer Institute MedStar Washington Hospital Center